116 related articles for article (PubMed ID: 21213498)
1. Synergistic growth-inhibitory effects of fenretinide with either cisplatin or paclitaxel on human epithelial ovarian cancer cell line (SKOV-3).
ImAim C; Chicharoen S; Reungrairatanaroj P; Liabsuetrakul T
J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S85-9. PubMed ID: 21213498
[TBL] [Abstract][Full Text] [Related]
2. Proteasome Inhibitor MG132 Enhances Sensitivity to Cisplatin on Ovarian Carcinoma Cells In Vitro and In Vivo.
Guo N; Peng Z; Zhang J
Int J Gynecol Cancer; 2016 Jun; 26(5):839-44. PubMed ID: 27051056
[TBL] [Abstract][Full Text] [Related]
3. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
5. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
van Haaften C; Boot A; Corver WE; van Eendenburg JD; Trimbos BJ; van Wezel T
J Exp Clin Cancer Res; 2015 Apr; 34(1):38. PubMed ID: 25907439
[TBL] [Abstract][Full Text] [Related]
7. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
9. Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo.
Lu X; Wang L; Mei J; Wang X; Zhu X; Zhang Q; Lv J
Biochem Biophys Res Commun; 2013 Jun; 435(3):385-90. PubMed ID: 23665331
[TBL] [Abstract][Full Text] [Related]
10. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity.
Formelli F; Cleris L
Cancer Res; 1993 Nov; 53(22):5374-6. PubMed ID: 8221674
[TBL] [Abstract][Full Text] [Related]
11. [Effects of DCC gene on cell growth and chemosensitivity of ovarian epithelial carcinoma cells].
Zhuang RJ; Li PL; Yu HW; Li HM
Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):334-8. PubMed ID: 17673047
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells.
Li S; Yang L; Wang J; Liang F; Chang B; Gu H; Wang H; Yang G; Chen Y
Oncotarget; 2016 Aug; 7(35):57145-57159. PubMed ID: 27494891
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
Masuyama H; Nakamura K; Nobumoto E; Hiramatsu Y
Int J Oncol; 2016 Sep; 49(3):1211-20. PubMed ID: 27572875
[TBL] [Abstract][Full Text] [Related]
15. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.
Singh RK; Gaikwad SM; Jinager A; Chaudhury S; Maheshwari A; Ray P
Cancer Lett; 2014 Nov; 354(2):254-62. PubMed ID: 25157649
[TBL] [Abstract][Full Text] [Related]
16. Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth.
Song Y; Xin X; Zhai X; Xia Z; Shen K
Arch Gynecol Obstet; 2015 Jan; 291(1):143-50. PubMed ID: 25118834
[TBL] [Abstract][Full Text] [Related]
17. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
[TBL] [Abstract][Full Text] [Related]
18. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
Yan XJ; Liang LZ; Zeng ZY; Shi Z; Fu LW
Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
[TBL] [Abstract][Full Text] [Related]
19. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
Kalemkerian GP; Ou X
Cancer Chemother Pharmacol; 1999; 43(2):145-50. PubMed ID: 9923820
[TBL] [Abstract][Full Text] [Related]
20. Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.
Gamarra-Luques CD; Hapon MB; Goyeneche AA; Telleria CM
J Ovarian Res; 2014; 7():45. PubMed ID: 24795781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
